Xeris Biopharma Holdings financials
$9.98+1.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $92.1M | $83.1M | $85.8M | $74.4M | $71.5M | $60.1M | $60.1M | $54.3M | $48.1M | $40.6M | $44.4M | $48.3M |
| Gross profit | $79.6M | $72.6M | $74.9M | $63.4M | $59.6M | $51.4M | $50.6M | $40.7M | $40.3M | $34.7M | $36.8M | $40.1M |
| Gross margin | 86.4% | 87.3% | 87.2% | 85.2% | 83.4% | 85.5% | 84.2% | 75.0% | 83.8% | 85.3% | 82.9% | 83.0% |
| Operating income | $5.2M | $7.9M | $16.8M | $6.7M | $4.5M | -$3.1M | $1.7M | -$12.9M | -$8.2M | -$14.2M | -$7.7M | -$4.0M |
| Net income | -$31.1M | $2.2M | $11.1M | $621.0K | -$1.9M | -$9.2M | -$5.1M | -$15.7M | -$15.0M | -$19.0M | -$13.4M | -$12.2M |
| Net margin | −33.8% | 2.7% | 12.9% | 0.8% | −2.7% | −15.3% | −8.5% | −29.0% | −31.2% | −46.7% | −30.2% | −25.2% |
| Diluted EPS | $-0.18 | $0.01 | $0.06 | $0.00 | $-0.01 | $-0.06 | $-0.03 | $-0.11 | $-0.10 | $-0.14 | $-0.10 | $-0.09 |
| EBITDA | $8.2M | $11.0M | $19.8M | $9.8M | $7.5M | -$65.0K | $4.7M | -$9.9M | -$5.2M | -$11.2M | -$9.8M | -$1.8M |
| Operating cash flow | $8.3M | $9.9M | $20.0M | $18.4M | $182.0K | -$10.0M | $2.0M | -$8.3M | -$10.3M | -$20.3M | $7.5M | -$14.6M |
| Free cash flow | $8.1M | $9.5M | $19.7M | $18.4M | -$97.0K | -$10.0M | $1.8M | -$8.4M | -$10.7M | -$20.5M | $7.3M | -$15.0M |
| Diluted shares | 172.8M | 177.6M | 201.4M | 177.6M | 159.5M | 152.4M | 149.2M | 149.0M | 148.3M | 140.5M | 138.2M | 138.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $121.7M | $111.8M | $111.0M | $91.6M | $59.3M | $58.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $252.6M | $221.2M | $220.3M | $219.5M | $218.6M | $229.8M |
| Total assets | $411.9M | $392.0M | $383.5M | $370.2M | $334.7M | $315.5M |
| Total liabilities | $421.6M | $379.0M | $369.8M | $371.1M | $354.0M | $350.6M |
| Shareholders' equity | -$9.7M | $13.0M | $13.7M | -$861.0K | -$19.3M | -$35.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology